课题基金 / 基金详情

Exacerbation of Alzheimer's Disease by Nitrous Oxide

Exacerbation of Alzheimer's Disease by Nitrous Oxide
一氧化二氮会加剧阿尔茨海默病
批准号:
6576030
负责人:
W ANDREW KOFKE
金额:
$7.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-30 至 2005-08-31

项目摘要

项目成果

W ANDREW KOFKE的其他基金

相似基金

相关文献

中文摘要
翻译
研究主题:3.阿尔茨海默病药物发现。最近的临床报告表明,阿尔茨海默病(AD)的发病较早,既往有轻微的神经学侮辱,或有更多的先前麻醉暴露。麻醉病史的具体特征易导致这种较早的AD发病尚不清楚,但此类观察引发了人们的担忧,即麻醉可能构成轻微的神经侮辱。NMDA拮抗剂,如一氧化二氮(N20)和MK801,已被证明在正常啮齿动物中具有双峰剂量相关的保护作用,然后是神经毒性作用,在人类中报道了相同的区域激活N20。 大量数据表明,神经兴奋伴随的氧化损伤在AD的发病机制中起着重要作用。因此,有理由认为阿尔茨海默病的发生与先前的N20接触之间存在相互作用。临床上,N20是一种非常常见的麻醉剂,几乎每个人在一生中的某个时候都会接触到这种麻醉剂。这使得其在AD发病机制中的应用成为一个合理且潜在的非常重要的领域。 我们假设,N20暴露具有剂量相关的双峰效应,可以减弱或加重随后发展成的AD。我们将检验以下具体假设: 1.大剂量N20暴露可加重AD的认知功能障碍和脑损伤。在AD转基因模型中,小鼠将在中年或老年期间接受5次高剂量的N20暴露,然后在10个月大时进行认知评估,分析脑中异前列腺素作为过氧化和可溶和不可溶淀粉样蛋白的标志,并对淀粉样斑块、细胞凋亡和神经元变性进行形态评估。 2.低剂量重复暴露N20可减轻AD患者的认知功能障碍和脑损伤。在AD转基因模型中,从中年到老年,小鼠每晚都会接受低剂量的N20,然后在10个月大时进行认知评估,分析大脑中的异前列腺素以及可溶和不可溶的淀粉样蛋白,并对淀粉样斑块、细胞凋亡和神经元变性进行形态评估。 麻醉与老年人术后认知功能障碍(POCD)有关,也被认为与AD的早期发病有关。这项拟议的研究将探索一种具有神经兴奋性副作用的普遍存在的麻醉剂在相关的阿尔茨海默病小鼠模型中的潜在作用。这将有助于有重点地评价 POCD的潜在原因,其结果将改变麻醉实践,从而显着降低老年人POCD的发生率,并可能对AIzheimer病的流行病学产生影响。此外,对保护作用的观察可能会导致发现一种易于实施的AD预防性药物疗法。
英文摘要
Research Topic: 3. Alzheimer's Disease Drug Discovery. Recent clinical reports indicate that the onset of Alzheimer's disease (AD) is earlier with prior mild neurologic insults or with increasing prior anesthetic exposure. The specific characteristics of anesthesia history that predispose to this earlier onset of AD are unknown but such observations raise the concern that something about anesthesia may constitute a mild neurologic insult. NMDA antagonists such as nitrous oxide (N20) and MK801 have been demonstrated to have a bimodal dose-related protective and then neurotoxic effect in normal rodents, with congruent regional activation by N20 reported in humans. There is ample data indicating an important role for neuroexcitation with associated oxidative injury in the pathogenesis of AD. It thus becomes reasonable to suggest an interaction between the genesis of AD and prior N20 exposure. Clinically N20 is an extremely common anesthetic with virtually ubiquitousexposure by almost everyone at some point in life. This makes its use a reasonable and potentially immensely important area to explore in the pathogenesis of AD. We hypothesize that N20 exposure has a bimodal dose-related effect to either attenuate or exacerbate subsequently developed AD. We will test the specific hypotheses that: 1. High dose N20 exposure exacerbates cognitive dysfunction and brain damage with AD. In a transgenic model of AD, mice will receive five high-dose exposures to N20 during middle-aged, or elderly ages followed at age 10 months by cognitive assessment, analysis of brain isoprostanes as markers of peroxidation and soluble andinsoluble amyloid, and morphologic assessment for amyloid plaques, apoptosis and neuronal degeneration 2. Low dose repetitive N20 exposure attenuates cognitive dysfunction and brain damage with AD. In a transgenic model of AD, mice will receive low doses of N20 nightly from mid-life to elderly ages, followed at age 10 months by cognitive assessment, analysis of brain isoprostanes and soluble and insoluble amyloid, and morphologic assessment for amyloid plaques, apoptosis and neuronal degeneration. Anesthesia has been implicated in postoperative cognitive dysfunction (POCD) in the elderly and has been impugned in the early onset of AD. The proposed research will explore the potential contribution of a ubiquitous anesthetic with neuroexcitatory side effects in a relevant murine model of AD. This will contribute to a focussed evaluation of the potential causes of POCD the results of which will change the practice of anesthesia and thus significantly attenuate the incidence of POCD in the elderly and possibly impact on the epidemiology of AIzheimer's disease. Moreover, observation of a protective effect may result in discovery of an easily implemented preventative drug therapy for AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prescribed opioid induced brain damage in chronic pain patients
  • 批准号:
    10473879
  • 项目类别:
  • 资助金额:
    $20.31万
  • 财政年份:
    2021
  • 负责人:
    W ANDREW KOFKE
  • 依托单位:
Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor
  • 批准号:
    9222821
  • 项目类别:
  • 资助金额:
    $63.54万
  • 财政年份:
    2014
  • 负责人:
    W ANDREW KOFKE
  • 依托单位:
Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor
  • 批准号:
    9021009
  • 项目类别:
  • 资助金额:
    $62.78万
  • 财政年份:
    2014
  • 负责人:
    W ANDREW KOFKE
  • 依托单位:
Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor
  • 批准号:
    8696339
  • 项目类别:
  • 资助金额:
    $44.25万
  • 财政年份:
    2014
  • 负责人:
    W ANDREW KOFKE
  • 依托单位:
海外基金